125 related articles for article (PubMed ID: 31091037)
1. [New therapeutic strategies in advanced stage breast and tubo-ovarian cancers].
Nikolopoulou A; Galli-Vareia I; Stravodimou A; Sarivalasis A; Zaman K
Rev Med Suisse; 2019 May; 15(651):1027-1031. PubMed ID: 31091037
[TBL] [Abstract][Full Text] [Related]
2. [From poly(ADP-ribose) discovery to PARP inhibitors in cancer therapy].
Schreiber V; Illuzzi G; Héberlé E; Dantzer F
Bull Cancer; 2015 Oct; 102(10):863-73. PubMed ID: 26384693
[TBL] [Abstract][Full Text] [Related]
3. [Abnormalities of DNA repair and gynecological cancers].
Auguste A; Leary A
Bull Cancer; 2017 Nov; 104(11):971-980. PubMed ID: 29054544
[TBL] [Abstract][Full Text] [Related]
4. Clinical Application of Poly(ADP-Ribose) Polymerase Inhibitors in High-Grade Serous Ovarian Cancer.
Parkes EE; Kennedy RD
Oncologist; 2016 May; 21(5):586-93. PubMed ID: 27022037
[TBL] [Abstract][Full Text] [Related]
5. Development of poly(ADP-ribose) polymerase inhibitors in the treatment of BRCA-mutated breast cancer.
Sulai NH; Tan AR
Clin Adv Hematol Oncol; 2018 Jul; 16(7):491-501. PubMed ID: 30067621
[TBL] [Abstract][Full Text] [Related]
6. Advances in PARP inhibitors for the treatment of breast cancer.
Dizdar O; Arslan C; Altundag K
Expert Opin Pharmacother; 2015; 16(18):2751-8. PubMed ID: 26485111
[TBL] [Abstract][Full Text] [Related]
7. Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1/2 mutated patients with advanced ovarian cancer.
Rafii S; Gourley C; Kumar R; Geuna E; Ern Ang J; Rye T; Chen LM; Shapira-Frommer R; Friedlander M; Matulonis U; De Greve J; Oza AM; Banerjee S; Molife LR; Gore ME; Kaye SB; Yap TA
Oncotarget; 2017 Jul; 8(29):47154-47160. PubMed ID: 28454085
[TBL] [Abstract][Full Text] [Related]
8. [Medical treatment options in BRCA-associated cancers].
Kahán Z
Magy Onkol; 2020 Mar; 64(1):13-24. PubMed ID: 32181758
[TBL] [Abstract][Full Text] [Related]
9. Diverse
Weigelt B; Comino-Méndez I; de Bruijn I; Tian L; Meisel JL; García-Murillas I; Fribbens C; Cutts R; Martelotto LG; Ng CKY; Lim RS; Selenica P; Piscuoglio S; Aghajanian C; Norton L; Murali R; Hyman DM; Borsu L; Arcila ME; Konner J; Reis-Filho JS; Greenberg RA; Robson ME; Turner NC
Clin Cancer Res; 2017 Nov; 23(21):6708-6720. PubMed ID: 28765325
[No Abstract] [Full Text] [Related]
10. The status of poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors in ovarian cancer, part 2: extending the scope beyond olaparib and BRCA1/2 mutations.
Miller RE; Ledermann JA
Clin Adv Hematol Oncol; 2016 Sep; 14(9):704-11. PubMed ID: 27673289
[TBL] [Abstract][Full Text] [Related]
11. Emerging therapeutic modalities of PARP inhibitors in breast cancer.
Wang X; Shi Y; Huang D; Guan X
Cancer Treat Rev; 2018 Jul; 68():62-68. PubMed ID: 29870916
[TBL] [Abstract][Full Text] [Related]
12. Hereditary breast cancer: pathobiology, clinical translation, and potential for targeted cancer therapeutics.
Rubinstein WS
Fam Cancer; 2008; 7(1):83-9. PubMed ID: 17624601
[TBL] [Abstract][Full Text] [Related]
13. [BRCA1 and BRCA2 - pathologists starting kit].
Škapa P
Cesk Patol; 2016; 52(4):193-196. PubMed ID: 27869444
[TBL] [Abstract][Full Text] [Related]
14. The role of poly adenosine diphosphate ribose polymerase inhibitors in breast and ovarian cancer: current status and future directions.
Chionh F; Mitchell G; Lindeman GJ; Friedlander M; Scott CL
Asia Pac J Clin Oncol; 2011 Sep; 7(3):197-211. PubMed ID: 21884432
[TBL] [Abstract][Full Text] [Related]
15. [PARP inhibitors: new therapeutic agents in breast and ovarian cancer].
Mercier-Vogel L; Bodmer A; Castiglione M
Rev Med Suisse; 2011 May; 7(296):1137-40. PubMed ID: 21721203
[TBL] [Abstract][Full Text] [Related]
16. PARP inhibitor maintenance therapy for patients with platinum-sensitive recurrent ovarian cancer: a cost-effectiveness analysis.
Smith HJ; Walters Haygood CL; Arend RC; Leath CA; Straughn JM
Gynecol Oncol; 2015 Oct; 139(1):59-62. PubMed ID: 26303225
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of olaparib monotherapy in germline BRCA1/2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy.
Domchek SM; Aghajanian C; Shapira-Frommer R; Schmutzler RK; Audeh MW; Friedlander M; Balmaña J; Mitchell G; Fried G; Stemmer SM; Hubert A; Rosengarten O; Loman N; Robertson JD; Mann H; Kaufman B
Gynecol Oncol; 2016 Feb; 140(2):199-203. PubMed ID: 26723501
[TBL] [Abstract][Full Text] [Related]
18. The potential of PARP inhibitors in genetic breast and ovarian cancers.
Drew Y; Calvert H
Ann N Y Acad Sci; 2008 Sep; 1138():136-45. PubMed ID: 18837894
[TBL] [Abstract][Full Text] [Related]
19. PARP Inhibitors in Epithelial Ovarian Cancer: State of Art and Perspectives of Clinical Research.
Gadducci A; Guerrieri ME
Anticancer Res; 2016 May; 36(5):2055-64. PubMed ID: 27127105
[TBL] [Abstract][Full Text] [Related]
20. PARP inhibitors and epithelial ovarian cancer: an approach to targeted chemotherapy and personalised medicine.
Mukhopadhyay A; Curtin N; Plummer R; Edmondson RJ
BJOG; 2011 Mar; 118(4):429-32. PubMed ID: 21244617
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]